Alumnus and Former Oak Ridge Staff Scientist visits Monmouth College

10/23/2012

Dr. Mark Goodman ’69 will be visiting campus this week as part of our Alumni Distinguished Visitor program. Mark is a 1969 graduate of Monmouth College. He went on to complete his doctorate in Organic Chemistry from the University of Alabama and is currently Professor of Radiology, Psychiatry and Hematology and Oncology at Emory University School of Medicine, where he also serves as Director of PET Core, PET Chemistry, and the Radiopharmaceutical Discovery Lab.

Dr. Goodman pioneered developments at Oak Ridge National Laboratory, where Monmouth College students can study through an ACM off campus program.

Mark M. Goodman, PhD, received his bachelor’s degree in chemistry from Monmouth College and his doctorate in organic chemistry from the University of Alabama. After working as a chemist at Roswell Park Cancer Institute, he joined the Department of Radiology at Harvard University in 1978 to pursue the development of positron emitting carbohydrates and fatty acids. In fall 1980, he took a position as a staff scientist at Oak Ridge National Laboratory and worked on the development of single photon labeled fatty acids and carbohydrates. Dr. Goodman’s research led to the development of the methylbranched fatty acid [123I] BMIPP, which has been commercially introduced in Japan as Cardiodine. In 1987, Dr. Goodman moved to the University Of Tennessee Medical Center at Knoxville where he took the position of Associate Professor of Radiology and Director of Radiopharmaceutical Chemistry to help establish the University of Tennessee PET program. In 1993, Dr. Goodman moved to Emory University where he took the position of Professor of Radiology to establish a PET radiopharmaceutical research program.

Dr. Goodman’s research interests encompass positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracer development of oncology, brain and heart agents. His research has resulted in the translation of the first reported synthetic amino alicyclic acid radiolabeled with the PET radioelement fluorine-18 for imaging both intracranial tumors and prostate cancer in patients.